05Jun
What We Learned From FDA's Public Hearing On Cannabis
The much-anticipated public hearing last week at the U.S. Food and Drug Administration on cannabis and cannabis-derived compounds drew a wide audience of participants, with strong views on how the FDA should (or should not) regulate the controversial...
By:
Sheppard Mullin Richter & Hampton LLP
Related
The state of New Jersey kicked off 2020 with a number of new employment laws focused on independent ...
Read More >
The SEC has issued its final Regulation Best Interest (Reg BI), Form CRS Regulation, RIA Interpretat...
Read More >
Jones Day's global anti-human trafficking initiative promotes unprecedented collaboration between ou...
Read More >
Employers are struggling to determine how to respond to the 2019 novel coronavirus (2019-nCoV) outbr...
Read More >
Several Ward and Smith attorneys provided updates on some of the fastest-changing areas of employmen...
Read More >
In Teamsters Local Union 847 v Maple Leaf Sports and Entertainment, 2019 CanLII 95328 (ON LA), a par...
Read More >